MALDI-MS-based assays for cellular drug action and transport with rapifleX MPP

This webinar took place on November 18, 2020

Webinar Overview - MALDI-MS-based Assays for Cellular Drug Action and Transport with rapifleX MPP

MALDI-MS is a fast, label-free technology for assays in pharmaceutical R&D and chemical biology. Recently, CeMOS has pioneered MALDI-MS based cell assays for drug profiling and screening, in part in a collaboration with a pharma company. The first part of the webinar will present examples of MALDI-MS phenotypic and mechanistic cell assays. It will cover the discovery of potential cellular drug response markers, characterization of potent fatty acid synthase inhibitors. The second part will introduce the use of MALDI-MS instead of radioisotope- or fluorescence-based methods for investigation of cellular drug uptake,  assay automation and evaluation of drug-drug interactions mediated by the transporter OATP2B1. Characterization of this transporter, screening of 300 drugs for inhibition of uptake and IC50 calculation for hit compounds will be presented.

Key Learning Objectives

  • MALDI MS cell-based assays are a great label-free analytical tool for the investigation of transport processes
  • Cell-based screening of inhibitors can be achieved by using a pipetting robot combined with the MPP software on the rapifleX
  • The identification of substrates and especially inhibitors of transport proteins can reveal possible drug-drug interactions
  • MALDI MS cell assays can help to identify drug response markers, aid compound profiling, and enable future cell-based screening

Who Should Attend?

  • Assay development and screening experts in pharmaceutical R&D
  • Drug safety experts interested in in-vitro profiling of drug-drug interactions
  • Chemical biologists interested in other, label-free possibilities for analysis of compound action in cells
  • Mass spectrometry experts with a keen interest in innovative applications of MALDI MS


Prof. Dr. Carsten Hopf
Professor and Head of CeMOS  

Carsten Hopf is currently professor of bioanalytics and drug discovery at Mannheim Technical University. A trained neurochemist, Carsten obtained his PhD in biochemistry from University of Tübingen in collaboration with the Max-Planck-Institute for Developmental Biology. As an EMBO fellow, he continued his research at the Johns Hopkins University School of Medicine, in Baltimore, USA. From 2001 to 2014, he worked at Cellzome (since 2012 part of GlaxoSmithKline), a leading proteomics-based drug discovery company, eventually serving in its leadership team. Since 2005, he is a professor of bioanalytics, enjoying the best of both worlds by building bridges between academia and industry. Carsten heads the Center for Mass Spectrometry and Optical Spectroscopy (CeMOS) in Mannheim. He also serves as spokesman for the Pharma/Diagnostics public-private partnership for innovation M2Aind and is the industry liaison for the German Society of Biochemistry and Molecular Biology.

Melissa Unger, M.Sc
Scientist at CeMOS  

Melissa Unger received a B.Sc. and M.Sc. in biology from Würzburg University, specializing in Human Genetics and Pharmaceutical Biology. Since 2017 she has been a PhD student at CeMOS, and she has just submitted her PhD thesis to Heidelberg University. She has received the Tony B. Award of the Society for Laboratory Automation and Screening (SLAS) for her work on MALDI-MS assays of drug uptake and drug-drug interactions.  


For Research Use Only. Not for use in clinical diagnostic procedures.